AI Article Synopsis
- Juvenile pityriasis rubra pilaris is a rare inflammatory skin condition that currently lacks FDA-approved treatments and can be tough to manage with standard therapies.
- A 6-year-old boy achieved clear skin within 2 weeks after starting ixekizumab therapy, which has remained effective for 6 months.
- This case suggests ixekizumab could be a promising and quick treatment option for children suffering from this rare skin disorder.
Article Abstract
Juvenile pityriasis rubra pilaris is a rare inflammatory skin disorder currently without any FDA-approved treatments, and lesions can be refractory to conventional treatment with topical corticosteroids, methotrexate, and oral retinoids. We herein present a case of a 6-year-old boy who attained clearance of extensive juvenile pityriasis rubra pilaris within 2 weeks of starting ixekizumab therapy. Therapeutic effect has been durable at 6 months, and patient continues on therapy without adverse effects. Our case highlights a new, rapidly effective treatment option for pediatric patients with this rare condition.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/pde.15700 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- Pityriasis rubra pilaris (PRP) is a rare skin disease that looks a lot like psoriasis and affects the skin on the palms and soles.
- Some recent treatments using special medicines called monoclonal antibodies have shown good results for people with PRP.
- One case of an adult diagnosed with an unusual type of PRP showed major improvement after receiving a specific treatment and emphasized the importance of genetic testing in figuring out tricky skin diseases.
Rapid clearance of extensive juvenile pityriasis rubra pilaris with ixekizumab.
Pediatr Dermatol
November 2024
Harvard Medical School, Boston, Massachusetts, USA.
Article Synopsis
- Juvenile pityriasis rubra pilaris is a rare inflammatory skin condition that currently lacks FDA-approved treatments and can be tough to manage with standard therapies.
- A 6-year-old boy achieved clear skin within 2 weeks after starting ixekizumab therapy, which has remained effective for 6 months.
- This case suggests ixekizumab could be a promising and quick treatment option for children suffering from this rare skin disorder.
Follicular Psoriasis: A Case Report and Review of Literature.
Skin Appendage Disord
April 2024
Department of Dermatology and STD, University College of Medical Sciences and Guru Teg Bahadur Hospital, Delhi, India.
Article Synopsis
- Psoriasis is an autoimmune skin condition with many subtypes, including the lesser-known follicular psoriasis (FP), which presents as scaly bumps around hair follicles.
- A case study of a 31-year-old male with symmetrically itchy, scaly lesions was diagnosed with FP after utilizing dermoscopy and histopathology, resulting in successful treatment.
- The discussion highlights the rarity of FP, notes the potential role of immune cells and keratin 17 in its development, and calls for more research to better understand the condition and its diagnosis through dermoscopy.
Successful treatment of CARD14-negative juvenile Pityriasis rubra pilaris with Ustekinumab.
J Eur Acad Dermatol Venereol
June 2024
Department of Dermatology, University-Hospital Tuebingen, Tuebingen, Germany.
Juvenile Pityriasis Rubra Pilaris.
Dermatol Pract Concept
April 2023
Traditional Chinese Medicine Hospital of Shangyu, Shaoxing, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!